A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression
A Single-arm, Open-label, Multi-center Study to Investigate Efficacy and Safety of Lexapro on Acute Treatment of Severe Depression
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Beijing, China
-
Huzhou, China
-
Nanjing, China
-
Qingdao, China
-
Shanghai, China
-
Wuhan, China
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants diagnosed with major depressive disorder (MDD) according to Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV)
- Scores of greater than or equal to 30 on the Montgomery-Asberg Depression Rating Scale (MADRS) Exclusion Criteria:
- Pregnant or lactating female participants
- Participants who are previously or currently diagnosed with the following mental disorders by DSM-IV: organic mental disorder, schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self), schizoaffective disorder, delusional disorder, undifferentiated mental disorders and bipolar affective disorder, participants with history of drug abuse, including alcohol and drug abuse in the past 12 months
- Participants who have significant risk of suicide on clinical assessment (has a score of greater than or equal to 5 on item 5 of MADRS) or have made a serious suicide attempt within the past 6 months and have any contraindication to escitalopram
- Participants who have known history of serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease currently taking other psychotropic drugs and anticonvulsant agents or continuously taking benzodiazepines or sleeping pills for over five days in the past one week
- Participants who have history of seizure (sudden, uncontrolled muscle spasms and loss of consciousness resulting from abnormal brain function) disorder, brain injury, any history of known neurological disease (multiple sclerosis, degenerative diseases, parkinson disease and any movement disorders) and have multiple drug adverse reactions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Escitalopram
Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks.
Dose can be adjusted as per Investigator's discretion depending on participant's response.
|
Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks.
Dose can be adjusted as per Investigator's discretion depending on participant's response.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Remission Based on Montgomery-Asberg Depression Rating Scale (MADRS)
Time Frame: Week 8
|
Remission is defined as percentage of participants with MADRS total score less than or equal to10 at the endpoint (8 weeks).
The MADRS is a scale designed to measure depression severity and detects changes due to antidepressant treatment.
The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60.
Higher score represents a more severe condition.
|
Week 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Clinical Response Based on Montgomery-Asberg Depression Rating Scale (MADRS)
Time Frame: Baseline and Week 8
|
Clinical response is defined as greater than or equal to 50 percent change from Baseline in MARDS total scores at end point (8 weeks).
The MADRS is a scale designed to measure depression severity and detects changes due to antidepressant treatment.
The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60.
Higher score represents a more severe condition.
|
Baseline and Week 8
|
|
Percentage of Participants With Clinical Onset Based on Montgomery-Asberg Depression Rating Scale (MADRS)
Time Frame: Baseline and Week 8
|
Clinical onset is defined as the reduction rate of MADRS total score greater than or equal to 20 percent.
The MADRS is a scale designed to measure depression severity and detects changes due to antidepressant treatment.
The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60.
Higher score represents a more severe condition.
|
Baseline and Week 8
|
|
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 1, 2, 4 and 8
Time Frame: Baseline, Week 1, 2, 4 and 8
|
The MADRS is a scale designed to measure depression severity and detects changes due to antidepressant treatment.
The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60.
Higher score represents a more severe condition.
|
Baseline, Week 1, 2, 4 and 8
|
|
Change From Baseline in Hamilton Depression Rating Scale (HAM-D-17) Score at Week 1, 2, 4 and 8
Time Frame: Baseline, Week 1, 2, 4 and 8
|
The Hamilton Depression Rating (HAM-D-17) Scale is a 17-item scale used to assess the severity of depression in participants diagnosed with an affective disorder.
Items are scored from 0 to 4, the higher the score, the more severe the depression.
Questions are related to symptoms such as depressed mood, guilt feelings, suicide, sleep disturbances, anxiety levels and weight loss.
|
Baseline, Week 1, 2, 4 and 8
|
|
Change From Baseline in Hamilton Anxiety Scale (HAMA) Score at Week 1, 2, 4 and 8
Time Frame: Baseline, Week 1, 2, 4 and 8
|
The Hamilton Anxiety Rating (HAMA) Scale is a 14-item scale developed to measure the severity of symptoms such as anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, restlessness and other physical symptoms.
Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe).
|
Baseline, Week 1, 2, 4 and 8
|
|
Change From Baseline in Brain-Derived Neurotrophic Factor (BDNF) at Week 8
Time Frame: Baseline and Week 8
|
Serum BDNF levels normally decrease in participants suffering from Major Depressive Disorder (MDD) and the decrease is more prominent in participants with long disease course but this can also increase in response to antidepressants.
The enzyme-linked immunosorbent assay (ELISA) method will be used to evaluate the serum BDNF level before and after using escitalopram, and use it as a biological marker for predicting the early efficacy of taking antidepressants.
|
Baseline and Week 8
|
|
Change From Baseline in Short Form-12 (SF-12) Score at Week 8
Time Frame: Baseline and Week 8
|
The SF-12 health survey is the 12-item sub form of Short form (SF-36), investigating 8 health dimensions: physical functioning, role-physical, bodily pain, general health perceptions, vitality, social functioning, role-emotional, and mental health.
This 12-item scale measures health conditions and describes the level of general physical health state and mental health problems.
|
Baseline and Week 8
|
|
Change from Baseline in Plasma Drug Concentration at Week 1 and 8
Time Frame: Baseline, Week 1 and 8
|
Plasma concentration of study drug will be assessed in blood samples.
|
Baseline, Week 1 and 8
|
|
Number of Participants with Structural and Functional Changes in Magnetic Resonance Imaging (MRI) at Week 8
Time Frame: Baseline and Week 8
|
Major depressive disorder participants have distinctive prefrontal cortex, hippocampal atrophy (wasting away, or decrease in size, of a body organ) and amygdala function abnormalities.
Structural and functional MRI (body pictures created using magnetic waves to look at soft tissues of the body) can help to evaluate the efficacy of escitalopram on neural plasticity.
|
Baseline and Week 8
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Antidepressive Agents, Second-Generation
- Citalopram
Other Study ID Numbers
Other Study ID Numbers
- CR016300
- ESCITALDEP4001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.